8-K – Current report

On November 12, 2015 GlycoMimetics, Inc. (NASDAQ: GLYC) reported financial results for the third quarter ended September 30, 2015 (Filing, 8-K, GlycoMimetics, NOV 12, 2015, View Source [SID:1234508211]). As of September 30, 2015, GlycoMimetics had cash and cash equivalents of $53.8 million, which includes a $20.0 million milestone payment from Pfizer in August upon its initiation of a Phase 3 clinical trial for rivipansel.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company’s research and development expenses decreased slightly to $5.0 million for the quarter ended September 30, 2015 as compared to $5.1 million for the third quarter of 2014. The decrease was primarily attributable to a decrease in spending related to manufacturing and process development for the Phase 1/2 clinical trial of GMI-1271, offset by an increase in the related clinical costs associated with site initiations and patient enrollment for the Phase 1/2 clinical trial. GlycoMimetics is studying the safety, pharmacokinetics and efficacy of GMI-1271, when used in combination with chemotherapy in patients with acute myeloid leukemia (AML), in the ongoing Phase 1/2 clinical trial. The first patient in the trial was enrolled in May 2015. In addition, the preclinical development of GMI-1359, the company’s next drug candidate, resulted in increased expenses in manufacturing and for the toxicology studies required to support a potential investigational new drug (IND) application.

The company’s general and administrative expenses increased to $2.1 million for the quarter ended September 30, 2015 as compared to $1.6 million for the third quarter of 2014. The increase was primarily attributable to additional professional fees, including patent costs, market research studies, insurance and other costs associated with supporting public company operations, as well as increased stock-based compensation expense.

"We have made recent achievements across our clinical pipeline," said Rachel King, CEO of GlycoMimetics. "Enrollment for the rivipansel Phase 3 clinical trial is underway and our partner Pfizer has also initiated dosing in a Phase 1 trial of a subcutaneous formulation of rivipansel. We have completed enrollment for our Phase 1 trial of GMI-1271 in healthy volunteers, and are enrolling patients in our Phase 1/ 2 trial in AML. Additionally, three posters and one oral presentation of new data for both GMI-1271, a novel and proprietary E-selectin antagonist, and GMI-1359, an antagonist of E-selectin and CXCR4 in advanced preclinical studies, have been selected for presentation at the annual ASH (Free ASH Whitepaper) meeting in December. These accomplishments position us for multiple news opportunities in 2016 and support our focus on programs that may potentially transform the treatment both of sickle cell disease and AML."

10-Q – Quarterly report [Sections 13 or 15(d)]

(Filing, 10-Q, GlycoMimetics, NOV 12, 2015, View Source [SID:1234508205])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


OPKO 4Kscore Test Receives Category I CPT Code Approval

On OPKO Health, Inc. (NYSE:OPK) reported that the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel has granted a Category I CPT code for its 4Kscore Test, the only blood test that accurately identifies an individual patient’s risk for aggressive prostate cancer (Press release, Opko Health, NOV 12, 2015, View Source [SID:1234508212]). This important event upgrades the 4Kscore Test from a Category III Administrative code to a Category I CPT code, a designation reserved for established diagnostic tests, and will provide broader access to the 4Kscore Test to urologists and their patients across the United States.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The CPT Category I approval is recognition by the leading panel of medical experts in the United States that the 4Kscore Test is now an established diagnostic test addressing an important unmet medical need," said David Okrongly, Ph.D., President of OPKO Diagnostics. "The multiple peer-reviewed clinical studies, inclusion of the 4Kscore Test in the 2015 National Comprehensive Cancer Network (NCCN) guidelines for Prostate Cancer Early Detection, and the growing adoption of the test in the United States were key factors in the decision by the CPT Editorial Board reviewers."

"This is a major milestone for the 4Kscore Test toward providing access to the 4Kscore Test for all eligible patients," said Phillip Frost, M.D., OPKO’s Chairman and Chief Executive Officer. "We believe it will help streamline claims processing and accelerate further coverage and adoption decisions by payers, physicians, and patients."

About the 4Kscore Test

The 4Kscore is the only blood test that accurately identifies an individual patient’s risk for aggressive prostate cancer, the lethal form of prostate cancer. The 4Kscore uses a proprietary algorithm that incorporates the blood levels of four different prostate-derived kallikrein proteins: Total PSA, Free PSA, Intact PSA and Human Kallikrein-2 (hK2), plus the patient’s age, and other clinical information to calculate the percentage risk (probability) of finding a Gleason Score 7 or higher grade of prostate cancer. The four kallikrein panel of biomarkers utilized in the 4Kscore Test is based on over a decade of research conducted by scientists at Memorial Sloan-Kettering Cancer Center and leading European institutions and is included as a standard of care in the 2015 NCCN Prostate Cancer Early Detection Guidelines. The 4Kscore Test provides individualized risk for the presence of aggressive prostate cancer and adds new information to the shared decision making discussion between the Urologist and the patient.

About Category I CPT Codes

In addition to facilitating reimbursement in government programs such as Medicare and Medicaid, CPT codes are used by other insurance companies and government payers to describe health care services and procedures. The AMA CPT Editorial Panel has established criteria for Category I designation of new diagnostic tests and the details are available on the AMA website. In summary, the Category I criteria include: performance of the test in an appropriately regulated laboratory environment, ordering of the test by many physicians and at a volume consistent with the intended clinical use, demonstration that the use of the test is consistent with current medical guidelines, and published scientific evidence of clinical efficacy.

10-Q – Quarterly report [Sections 13 or 15(d)]

(Filing, 10-Q, Juno, NOV 12, 2015, View Source [SID:1234508208])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Celator® Pharmaceuticals Announces Third Quarter 2015 Financial Results and Business Update

On November 12, 2015 Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) reported business highlights and financial results for the third quarter ended September 30, 2015 (Press release, Celator Pharmaceuticals, NOV 12, 2015, View Source [SID:1234508214]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The momentum builds as we continue to deliver on our milestones, from the induction response rate improvement observed in our Phase 3 study with VYXEOS (formerly CPX-351) and announced last quarter, to impressive results from data packages on novel combination programs," said Scott Jackson, Chief Executive Officer of the Company. "The external validation of our proprietary technologies, as evidenced with VYXEOS being selected as the Nanomedicine Product of the Year is very exciting. We expect the overall survival data from the Phase 3 study in the first quarter of 2016."

Third Quarter 2015 and Recent Highlights:

Celator will receive more than $1.675 million from the sale of its net operating losses and research and development credits under the New Jersey Technology Business Tax Certificate Transfer Program. The Company expects to receive this amount by the end of 2015.

Pre-clinical data presented at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) demonstrated the broad applicability of Celator’s hydrophobic prodrug nanoparticle (HPN) delivery technology to molecularly targeted agents, including inhibitors of MEK, Akt, HSP90 and B-Raf. Significant efficacy improvements for HPN co-formulated combinations over conventional administration of targeted agent regimens were reported.

VYXEOS (formerly CPX-351) was selected the Best Nanomedicine Product of the Year by a panel of pharmaceutical industry specialists that recognizes innovative product developments in nanomedicine.

Celator announced top-line results from an intensive QT/QTc study showing VYXEOS has no QT/QTc interval prolongation and that additional data will be presented at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting. This study was conducted to support the New Drug Application for VYXEOS which the Company plans to file in the third quarter of 2016.
The Independent Data and Safety Monitoring Board (DSMB) for the Company’s Phase 3 clinical study with VYXEOS has completed the final pre-planned safety review of all patients and has again recommended the study continue as planned without any modifications.

Patients began enrolling in an investigator-initiated Phase 2 clinical study evaluating VYXEOS as a treatment for patients with newly diagnosed acute myeloid leukemia (AML) at high risk for induction treatment mortality.

Celator’s senior management team hosted an Analyst and Investor Day to discuss the company’s growth strategy, its lead product candidate, VYXEOS, and its proprietary CombiPlex technology platform.

Michael R. Dougherty was appointed Executive Chairman of the Board of Directors. Mr. Dougherty has been a director of Celator since July 2013 and served as Chairman since September 2014.

Financial Highlights:

Cash Position: Cash and cash equivalents as of September 30, 2015 were $24.1 million, compared to $32.4 million as of December 31, 2014. The decrease was primarily due to $13.3 million of net cash used in operating activities, partially offset by $5.0 million in proceeds from the final draw down of the Hercules Technology Growth Capital loan. Cash and cash equivalents as of June 30, 2015 were $28.5 million. Management believes that the cash and cash equivalents at September 30, 2015 will be sufficient to meet estimated working capital requirements and fund planned operations into the second half of 2016.

R&D Expenses: Research and development expenses were $2.9 million and $9.0 million for the three and nine months ended September 30, 2015, as compared to $3.3 million and $9.2 million for the same periods in 2014. The decrease in R&D expenses in the comparable three-month and nine-month periods were primarily due to decreases in regulatory and clinical trial costs related to the Phase 3 study of VYXEOS and manufacturing and drug costs.

G&A Expenses: General and administrative expenses were $1.9 million and $5.7 million for the three and nine months ended September 30, 2015, as compared to $1.9 million and $5.5 million for the same periods of 2014. The increase in the comparable nine-month period was primarily attributable to increases in compensation, public company expenses and professional fees offset by reductions in consulting and recruiting fees.

Net Loss: Net loss was $5.2 million and $14.9 million for the three and nine months ended September 30, 2015, as compared to $5.5 million and $14.5 million for the same periods in 2014.